ProPetro Q2 revenue rises 13%, slightly beats estimates
Reuters2026/07/29 11:12
Overview
U.S. oilfield services firm's Q2 revenue rose 13%, slightly beating analyst expectations
Adjusted EBITDA for Q2 missed analyst estimates
Results impacted by new fleet startup costs, deployment downtime, and severe weather
Outlook
Company expects 2026 capital expenditures of $525 mln to $595 mln, down from prior $540 mln-$610 mln range
Completions business 2026 capex seen at $125 mln-$145 mln, down from $140 mln-$160 mln prior guidance
Company expects to activate thirteenth frac fleet later in Q3 2026 amid rising customer demand
Result Drivers
HIGHER UTILIZATION - Co said Q2 revenue growth was primarily driven by increased utilization in the completions business and incremental deployments in PROPWR
OPERATIONAL DISRUPTIONS - Upfront costs for new fleet, unexpected downtime, and severe weather negatively impacted results
PROPWR COMMERCIAL PROGRESS - Co reported increased contracted power generation capacity and ongoing expansion in data center, oil and gas, and industrial markets
Company press release: ID:nBw77cqwa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Revenue |
Slight Beat* |
$306 mln |
$304.41 mln (8 Analysts) |
Q2 Net Loss |
|
$8.11 mln |
|
Q2 Adjusted EBITDA |
Miss |
$45 mln |
$52.34 mln (10 Analysts) |
Q2 Capex |
|
$61 mln |
|
Q2 EBIT |
|
-$3.18 mln |
|
Q2 Pretax Loss |
|
$2.18 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Reuters Recommended Reads
July 28 - NOV Inc Q2 revenue beats estimates, helped by offshore project strength
July 28 - Canada's Trican Q2 revenue slightly misses estimates on weather-related slowdown
July 28 - Nabors Q2 revenue misses estimates on lower rig activity
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ
NASDAQ TRADE HALT CONTINUES <EFTY.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:28 AM